METHOD FOR COMBINED IMAGING AND TREATING ORGANS AND TISSUES

• US 20120190925A1
• Filed: 01/25/2012
• Published: 07/26/2012
• Est. Priority Date: 01/25/2011
• Status: Abandoned Application

• Current Assignee: Oncofluor, Inc.
• Original Assignee: Oncofluor, Inc.
• Inventors: Luiken, George A.
• Application Number:
  US13/358,380
• Publication Number:
  US 20120190925A1
• Time in Patent Office: Days
• US Class Current: 600/139
• CPC Class Codes: A61B 1/00165 with light-conductive means, e.g. fibre optics A61B1/07 takes precedence
• CPC Class Codes: A61B 1/043 for fluorescence imaging
• CPC Class Codes: A61B 1/0638 providing two or more wavelengths
• CPC Class Codes: A61B 1/0669 at proximal end of an endoscope
• CPC Class Codes: A61B 1/0692 head mounted
• CPC Class Codes: A61B 18/20 using laser
• CPC Class Codes: A61B 5/0071 by measuring fluorescence emission
• CPC Class Codes: A61K 47/6807 the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
• CPC Class Codes: A61K 49/0058 Antibodies
• CPC Class Codes: A61K 51/1045 against animal or human tumor cells or tumor cell determinants
• CPC Class Codes: A61K 51/1051 the tumor cell being from breast, e.g. the antibody being herceptin
• CPC Class Codes: A61K 51/1054 the tumor cell being from lung
• CPC Class Codes: A61K 51/106 the tumor cell being from kidney or bladder
• CPC Class Codes: A61K 51/1063 the tumor cell being from stomach or intestines
• CPC Class Codes: A61K 51/1066 the tumor cell being from skin
• CPC Class Codes: A61K 51/1072 the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate

Abstract

The present invention provides methods and compositions for detecting and treating malignant tissue, organs or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus or by a route providing access to the tissue or organ, with a composition comprising a monoclonal antibody (chimeric, humanized, fully human), partial antibody, Fab Fragment, antibody fragment that is tagged with a fluorophore with or without the addition of a therapeutic chemotherapy molecule, which specifically binds to the targeted organ, tissue or cell. Resection of the primary malignant tissue within the mammalian species (using the fluorescence of the fluorescing targeting construct) provides the advantage of identifying all bulk tumor as fluorescent at the time of the original tumor resection.

Claims

1. A method for in vivo diagnosis, visualization or therapy of residual diseased tissue in a subject in need thereof comprising:

(a) illuminating an in vivo exposed body cavity, integument, or organ of a subject containing diseased tissue with light having at least one excitation wavelength in the range from about 401 nm to about 510 nm;

(b) directly viewing the illuminated cavity, integument, or organ with or without the aid of an endoscope fluorescence emitted from the body cavity or organ in response to the light from a fluorescent targeting construct comprising a fluorophore-tagged tumor-specific antibody or a fluorophore-tagged tumor avid moiety and a therapeutic isotope molecule, wherein the fluorophore-tagged antibody or fluorophore-tagged tumor avid moiety is responsive to the excitation wavelength administered to the subject and which has specifically bound to and/or been taken up by the diseased tissue in the exposed body cavity or organ; and

(c) determining by direct visualization without the aid of a capture device the location and/or surface area of the diseased tissue in the subject from the fluorescence provided by the targeting construct.

2. The method of claim 1, wherein the fluorophore-tagged antibody is an anti-tumor antigen antibody, FAB fragment, bispecific antibody, or a functional antibody fragment thereof.

3. The method of claim 1, wherein the therapeutic molecule is any derivative of the chemotherapy compounds as listed antimetabolites, antibiotics, anthracyclines, tubulin inhibitors, taxanes, mTOR inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, epithilones, multi-kinase inhibitors.

4. The method of claim 1, wherein the excitation light is substantially lacking in wavelengths greater than about 510 nm.

5. The method of claim 1, wherein the tumor-avid moiety is a hormone, a hormone receptor, binding-peptide, deoxyglucose, somatostatin, a somatostatin receptor-binding peptide, methionine, histidine, folic acid, cinacalcet or a combination of any two or more thereof.

6. The method of claim 5, wherein the hormone receptor binding-peptide is HER2 neu, an estrogen receptor, a progesterone receptor, an androgen receptor, a TSH receptor, or a calcium sensing receptor, vascular endothelial growth factor receptor, insulin-like receptor, platelet-derived growth factor receptor.

7. The method of claim 5, wherein the tumor-avid moiety is chromagranin, somatostatin or a somatostatin receptor-binding peptide, or cinacalcet.

8. The method of claim 5, wherein the diseased tissue is a neuroendocrine or endocrine tumor.

9. The method of claim 8, wherein the tumor is thyroid cancer, parathyroid adenoma, adrenal cancer, islet cell cancer, pituitary adenoma, insulinoma, or pinealoma.

10. The method of claim 8, wherein the tumor is malignant melanoma, head and neck cancer, hepatic cancer, breast cancer, pancreas cancer, small cell and non-small cell lung cancer, ovarian, endometrial, or fallopian tube cancer, pituitary or adrenal cancer, brain cancer, esophageal, gastric, small bowel or colorectal cancer, anal cancer;

basal cell cancer, squamous cell cancer of the skin, epithelial cancer, carcinoid tumor, prostate cancer, bladder cancer, renal cancer, vulvar cancer and testicular germ cell tumor, Ewing'"'"'s sarcoma, soft tissue sarcoma, or osteosarcoma, hemangiopericytoma, hemangiomatosis, lymphangiomatosis.

11. The method of claim 5, wherein the somatostatin receptor-binding peptide is octreotide, lanreotide, P587 or P829.

12. The method of claim 1, wherein the tumor-avid moiety is deoxyglucose.

13. The method of claim 12, wherein diseased tissue is malignant melanoma, head and neck cancer, hepatic cancer, breast cancer, pancreas cancer, small cell and non-small cell lung cancer, ovarian, endometrial, or fallopian tube cancer, pituitary or adrenal cancer, brain cancer, esophageal, gastric, small bowel or colorectal cancer, anal cancer;

basal cell cancer, squamous cell cancer of the skin, epithelial cancer, carcinoid tumor, prostate cancer, bladder cancer, renal cancer, vulvar cancer and testicular germ cell tumor, Ewing'"'"'s sarcoma, soft tissue sarcoma, or osteosarcoma, hemangiopericytoma, hemangiomatosis, lymphangiomatosis.

14. The method of claim 1, wherein the tumor-avid moiety is 1-amino-cyclobutane-1-carboxylic acid, methionine, or a methionine derivative, histidine.

15. The method of claim 1, further comprising surgically excising at least a part of the diseased tissue while directly viewing the illuminated cavity, integument, or organ.

16. The method of claim 1, wherein the surface area determined is based on the intensity of the fluorescence.

17. The method of claim 1, wherein the light is substantially monochromatic and the wavelength is matched to a predominant excitation wavelength of the fluorescent targeting construct.

18. The method of claim 17, wherein the excitation wavelength is about 400-510 nm and the fluorescent targeting construct comprises fluorescein, fluorescein derivatives, Alexa-Fluor 488, Hi-Lyte Fluor 488, quinine, tetracycline.

19. The method of claim 1, wherein the exposed body cavity is a natural body cavity.

20. The method of claim 1, wherein the exposed organ is a muscle tumor, bone tumor, malignant mole, a thyroid mass, a brain tumor, a testicular cancer, or a prostate cancer.

21. The method of claim 1, wherein the exposed body cavity is made surgically or the exposed body cavity is viewed through an endoscope (rigid or flexible), or through the use of robotic devices.

22. The method of claim 1, wherein a source of the light is located outside of the body of the subject.

23. The method of claim 1, wherein the viewing is for monitoring the course of the disease state.

24. The method of claim 1, wherein the viewing identifies the diseased tissue for surgical intervention.

25. The method of claim 1, further comprising surgically removing all or at least a portion of the diseased tissue.

26. The method of claim 1, wherein the diseased tissue is associated with a condition selected from the group consisting of tumors, pre-cancerous conditions, or necrotic and ischemic conditions.

27. The method of claim 1, wherein the fluorescing targeting construct further comprises a linker moiety for attaching the antibody or the tumor avid moiety to the fluorescing moiety.

28. The method of claim 27, wherein the tumor-avid moiety is a hormone, deoxyglucose, somatostatin, a somatostatin receptor-binding peptide, methionine, a methionine derivative, or a combination of any two or more thereof.

29. The method of claim 1, wherein the targeting construct is administered by a method selected from the group consisting of intravenously, intramuscularly, intraarticularly, intracisternally, intraocularly, intraventricularly, intrathecally, intercavitarily, intraperitoneally, intradermally, and a combination of any two or more thereof.

30. The method of claim 1, wherein the targeting construct is administered by local injection.

31. The method of claim 1, wherein the targeting construct is administered systemically.

32. A method for utilizing a diagnostic procedure during surgery in a subject in need thereof comprising:

(a) illuminating an in vivo exposed body cavity or organ of the subject exposed by surgery and that contains diseased tissue with light having at least one excitation wavelength in the range from about 401 nm to about 510 nm;

(b) directly viewing with or without the aid of an endoscope or robotic device, the fluorescence emanating from a fluorescent targeting construct comprising an fluorophore-tagged antibody or a fluorophore-tagged tumor avid moiety and a therapeutic isotope molecule, wherein the fluorophore-tagged antibody or fluorophore-tagged tumor avid moiety is responsive to the excitation wavelength which is administered to the subject and which has specifically bound to and/or been taken up by the diseased tissue in the body cavity or organ, and wherein the targeting construct fluoresces in response to the at least one excitation wavelength;

(c) determining the location and/or surface area of the diseased tissue in the subject from the directly viewed fluorescence from the targeting construct; and

(d) removing all or at least a portion of the diseased tissue.

33. The method of claim 32, wherein the light is substantially lacking in light having a wavelength greater than about 510 nm.

34. The method of claim 32, wherein the viewing of the fluorescence and the removing of the tumor tissue are performed substantially contemporaneously.

35. A method for in vivo diagnosis of tumor cells in a subject in need thereof comprising:

(a) contacting samples of tumor cells obtained from the subject in vitro with a plurality of detectably labeled compounds, each of which binds to one or more cell-surface tumor antigens or is selectively taken up by a distinct tumor type;

(b) determining which of the compounds is bound to cell-surface tumor antigens or taken up by the sample tumor cells;

(c) administering to the subject a diagnostically effective amount of at least one biologically compatible fluorescing targeting construct containing a compound determined in (b) that is tagged with a therapeutic isotope molecule to bind to and/or be taken up by exposed tumor tissue or organ that matches the sample tumor cells, which targeting construct fluoresces in response to light having at least one excitation wavelength in the range from about 401 nm to about 510 nm; and

(d) diagnosing the location and/or surface area of the exposed tumor tissue in the in vivo body cavity or organ by directly viewing with or without the aid of an endoscopic device for viewing the fluorescence emanating from the targeting construct bound to or taken up in the exposed tumor tissue or organ in response to illumination with the excitation light source.

36. The method of claim 35, wherein a PET scan is performed to prior to step (d) to identify tumor masses having the fluorescent targeting construct attached thereto, thereby providing information on the location of the diseased tissue in the body cavity or organ.